



The Michael J. Fox Foundation for Parkinson's Research & The New York Academy of Sciences
Parkinson's Disease Therapeutics Conference
New York, NY
September 30, 2009

Poster Session on Novel Therapeutic Targets and Tools

Thomas G. Beach, MD, PhD, Sun Health Research Institute – “Brain & Body Donation Program of the Arizona Parkinson's Disease Consortium”

Steven P. Braithwaite, PhD, Wyeth Pharmaceuticals – “Targeting LRRK2 for Drug Discovery”

Luke Esposito, PhD, ProteoTech Inc. “New Small Molecule Inhibiting Agents of Alpha-Synuclein & Lewy Body Formation as Disease-Modifying Treatments for Parkinson's Disease”

Mark Frasier, PhD, The Michael J. Fox Foundation – “The Parkinson's Progression Markers Initiative: A Prospective Biomarkers Study”

David Grabli, MD, Hôpital de la Salpêtrière – “Development of a New Primate Model of Postural Disturbance by Lesioning Non Cholinergic Neurons of the Reticular Formation”

Ann M. Graybiel and Jill Crittenden, MIT – “Evaluation of the Striatum-Enriched Genes, CalDAG-GEF1 and CalDAG-GEF2, as Targets for the Treatment and Prevention of L-DOPA Induced Dyskinesias”

Chenjian Li, PhD, Weill Medical College of Cornell University – “BAC-Engineered Alpha-Synuclein Transgenic Rats”

Pamela J. McLean, PhD, Harvard University – “Hsp90 as a Target for Neuroprotective Agents in Parkinson's Disease”

Michael T. Rogan, PhD, The Michael J. Fox Foundation – “PD Online Research: A Professional Collaborative Community for Rapid-Fire Problem Solving in Parkinson's Disease Science”